CDRD Ventures Inc (CVI) has launched a spin-off company with a novel platform technology that improves drug absorption for cancer treatments. Sitka Biopharma Inc's first chemotherapeutic treatment targets high-risk, non-muscle invasive bladder cancer. The technology was developed at the Univ of British Columbia with assistance from the Centre for Drug R&D and further advanced as a product candidate by CVI. Preclinical data show that Sitka's polymer platform technology improves absorption of catheter-based treatments for bladder cancer....